Revista colombiana de obstetricia y ginecologia最新文献

{"title":"Letter to the Editor about “Preoperative neutrophil/ lymphocyte ratio as prognostic factor in epitelial ovarian cancer”","authors":"Luis Ángel Cesar Huamanciza","doi":"10.18597/rcog.4278","DOIUrl":"10.18597/rcog.4278","url":null,"abstract":"","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"75 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11545602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor about the qualitative study on breastfeeding experiences: sociocultural limitations in the lives of breastfeeding women","authors":"Samir Steve Cusipuma Pariapuma, Alexandra Barrios Carpio, Mery Milagros Maldonado Ochoa","doi":"10.18597/rcog.4255","DOIUrl":"10.18597/rcog.4255","url":null,"abstract":"","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"75 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter to the Editor: qualitative study about breastfeeding experiences from the perspective of the breastfeeding woman","authors":"Diana C Londoño-Sierra, Sandra L Restrepo-Mesa","doi":"10.18597/rcog.4288","DOIUrl":"10.18597/rcog.4288","url":null,"abstract":"<p><p>Reply to the letter to the Editor</p>","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"75 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11563562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter to the Editor \"Treatment of ectopic pregnancy implanted on cesarean scar: other therapeutic approaches\".","authors":"Oswaldo Tipiani","doi":"10.18597/rcog.4260","DOIUrl":"10.18597/rcog.4260","url":null,"abstract":"<p><p>Reply to the letter to the Editor.</p>","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"75 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter to the Editor about “Preoperative neutrophil/lymphocyte ratio as prognostic factor in epitelial ovarian cancer”","authors":"Julio Vázquez Rojo","doi":"10.18597/rcog.4289","DOIUrl":"10.18597/rcog.4289","url":null,"abstract":"<p><p>Reply to the letter to the Editor</p>","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"75 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colombian consensus for the molecular diagnosis of endometrial cancer","authors":"Marc Edy Pierre, Angélica Viviana Fletcher Prieto, Juliana Rodríguez, Abraham Hernández Blanquisett, Ana Milena Gómez Camacho, Rafael Parra Medina, Lucrecia Mojica Silva, Robinson Fernández, Pedro Hernando Calderón Quiroz","doi":"10.18597/rcog.4060","DOIUrl":"10.18597/rcog.4060","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Objective: The Cancer Genome Atlas research program (TCGA) developed the molecular classification for endometrial cancer with prognostic and therapeutic utility, which was replaced by the ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) classification by consensus and international guidelines due to its high cost. This article aims to present national recommendations from an expert consensus that allows unification and implementation of the molecular classification for women with endometrial cancer nationwide, with a rational use of resources and technology.\u0000\u0000Methods: Consensus of 36 experts in clinical oncology, oncological gynecology, pathology, and genetics, with clinical practice in the national territory. The leader group performed a literature review and structuring of questions rated 1 to 9 points. A modified nominal group technique was used. There was a face-to-face meeting with master presentations, deliberative dialogue, and Google Forms (Google LLC, Mountain View, CA, USA) questionnaire voting with analysis and discussion of responses. The non-consensual responses led to a second round of voting. The final manuscript was finally prepared and revised.\u0000\u0000Results: Seven recommendations were formulated integrating the panelist responses based on evidence, but adjusted to the Colombian context and reality.\u0000\u0000Recommendation 1. The molecular classification is recommended in all the endometrial cancers using the immunohistochemistry markers as subrogated results from the molecular profile initially proposed in the TCGA classification.\u0000\u0000Recommendation 2. The sequential test strategy is recommended, starting with the immunohistochemistry markers (p53, MLH1, MSH 2, MSH6, PMS2) simultaneously in all the patients, defining to request POLE (DNA polymerase epsilon) (if available) according to the risk classification based on the surgical piece.\u0000\u0000Recommendation 3. It is recommended, that the gynecologist oncologist should be the one to request the POLE (if available) according to the final pathology report. This test must be requested for all endometrial cancers stage I-II, except in low risk (stage IA low grade endometrioid histology without linfovascular invasion normal p53) and, stages III-IV without residual disease, without affecting the request of subrogated immunohistochemistry molecular markers upon histology.\u0000\u0000The consensus proposes that the POLE is requested after the immunohistochemistry and according to the categories in the risk classification established by the 2020 ESGO/ESTRO/ESP guidelines.\u0000\u0000Recommendation 4. It is recommended to perform immunohistochemistry for hormonal receptors for all women with endometrial cancer and the HER2 in patients with p53abn, simultaneously with the others immunohistochemistry markers.\u0000\u0000Recommendation 5. It is recommended to perform the immunohistochemistry markers (p53, MLH1, MSH2, MSH6 y PMS2) in an initial endometrial biopsy or curettage when the specimen is adequate and availabl","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer","authors":"Marc E Pierre, Ray Manneh, Abraham Hernández, Juliana Rodríguez, Angélica V Fletcher, Heydi M Ramírez, Oscar M Niño, Diego A Gómez, Daniel Sanabria, Fernando Contreras, José R Pieschacón, Pedro H Calderón","doi":"10.18597/rcog.4094","DOIUrl":"10.18597/rcog.4094","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Introduction and objective: The approach to patients with advanced or metastatic high-grade epithelial ovarian cancer (EOC) has evolved over time with the advent of new therapies and multimodal strategies. The objective of this consensus of experts is to generate national recommendations for the profiling and management of advanced or metastatic high-grade OEC, defined as stages III and IV of the “The International Federation of Gynecology and Obstetrics (FIGO) classification at the time of diagnosis to base on the literature review that included international evidence-based clinical practice guidelines (CPG).\u0000\u0000Material and methods: Eleven panelists (oncologists and gynecological oncologists) answered 8 questions about the profiling and management of advanced or metastatic ovarian epithelial carcinoma. The panelists were chosen for their academic profile and\u0000\u0000influence in national health institutions. Guidelines from the “ESMO Standardized Operating Procedures Consensus Conference” were used to develop the consensus. It was agreed that the level of agreement to accept a recommendation should be ≥ 80%. The document was peer reviewed.\u0000\u0000Results: Eight general recommendations are made, which are presented into five domains. Some of these recommendations are subdivided into specific recommendations.\u0000\u0000Initial treatment\u0000\u0000Recommendation 1.1 Complete primary cytoreduction (PCS) surgery is suggested as the initial therapy of choice for patients with high-grade or metastatic EOC, which should ideally be carried out in centers with experience, followed by adjuvant therapy.\u0000\u00001.2 Neoadjuvant chemotherapy followed by interval cytoreduction surgery (ICS) is suggested in those who are unlikely to achieve a complete cytoreduction in PCS either due to unresectable metastatic disease or who present unresectability criteria (imaging, laparoscopic and/or by laparotomy) and that have been defined by a gynecological oncologist and patients with poor functional status and comorbidities according to the criteria of the multidisciplinary team (clinical oncology, gynecological oncology, radiology, etc.).\u0000\u0000Recommendation 2. In patients with high-grade epithelial ovarian cancer (EOC), in stage III locally advanced or metastatic, who received neoadjuvant chemotherapy and achieved a complete or partial response (cytoreduction with tumor residue &lt; 2.5 mm), the use of Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) could be considered as an alternative to standard platinum-based adjuvant intravenous chemotherapy during interval cytoreductive surgery, after discussion in a multidisciplinary tumor board, at a center experienced in treating this type of patients.\u0000\u0000Use of genetic testing.\u0000\u0000Recommendation 3. It is suggested at the time of diagnosis to offer molecular genetic testing to all patients with high-grade advanced or metastatic EOC regardless of family history.\u0000\u0000Recommendation 4. It is suggested to offer genetic counseling, by qualified personnel, to all patients with","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on the article entitled “Risk factors associated with insulin requirement in patients with gestational diabetes in a referral hospital in Buenos Aires, Argentina: retrospective cohort study”","authors":"Daniela Sofia Infante Paredes, Maria Gracia Consuelo Castro Trujillo, Alfredo Chiappe Gonzales","doi":"10.18597/rcog.4126","DOIUrl":"10.18597/rcog.4126","url":null,"abstract":"","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative neutrophil/lymphocyte ratio as prognostic factor in epithelial ovarian cancer","authors":"Julio Vázquez Rojo, Julio Vázquez Reguera, Angel Sánchez del Río","doi":"10.18597/rcog.4046","DOIUrl":"10.18597/rcog.4046","url":null,"abstract":"<p><strong>Objectives: </strong>To determine if there is an association between the neutrophil to lymphocyte ratio (NLR) and prognosis in patients with epithelial ovarian cancer (EOC) diagnosed and treated in a Spanish population.</p><p><strong>Material and methods: </strong>Retrospective cohort of patients with epithelial ovarian cancer who had neutrophil and lymphocyte values in complete blood count before the histopathological diagnosis and survival of at least three months, in an intermediate complexity hospital. Convenience sampling. Measured variables included age, menopausal stage, parity, International Federation of Gynecology and Obstetrics (FIGO) stage, treatment type, residual tumor, lymph node involvement, presence of ascites, cytology, histologic type, differentiation grade, and CA-125 values. Additionally, outcomes, overall survival, disease/progression-free survival were also measured. Bivariate inferential and Cox regression analyses were performed.</p><p><strong>Results: </strong>Out of 78 candidates, 60 women with EOC were included. Of them, 24 (40%) had a low NLR (≤ 2,9) while 36 (60%) had a high NLR (> 2,9). An association was found between high NLR levels and suboptimal cytoreductive surgery. High NLR ratios were associated with lower overall survival (Hazard ratio (HR): 4.1; 95% CI: 1.4-11.8) and lower 5-year disease-free survival (HR: 2.6; 95% CI: 1.2-5.7).</p><p><strong>Conclusions: </strong>A plasma neutrophil to lymphocyte ratio of more than 2.9 was associated with poor prognosis in patients with epithelial ovarian cancer in our setting. There is a need to establish the optimal cut-off point and conduct prospective studies with larger patient numbers in order to support this information.</p>","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11189650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent voluntary termination of pregnancy. Prevalence study and exploration of associated factors. Antioquia, Colombia, 2015 – 2021","authors":"Laura Andrea González-Pérez, Freddy Andrés Barrios Arroyave","doi":"10.18597/rcog.4018","DOIUrl":"10.18597/rcog.4018","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the prevalence of recurrent voluntary termination of pregnancy (VTP) and to explore associated factors.</p><p><strong>Materials and methods: </strong>Descriptive, cross-sectional cohort study which included women seen between 2015 and 2021 in five sites of an institution located in the Department of Antioquia which promotes sexual and reproductive health (SRH) care in Colombia. Measured variables included sociodemographics, SRH, recurrent performance of VTP, type of procedure used in the first VTP and contraception method selected afterwards. The prevalence of global and yearly recurrent abortion period is presented. Associated factors were explored using a multivariate analysis. The research committee of the institution approved the study.</p><p><strong>Results: </strong>In total, 20,423 women were included. The prevalence of recurrent VTP was 4.07% (n = 831) during the entire period, ranging between 2.3 and 6% over the 7 years. The most commonly used method for recurrent VTP was pharmacological induction (48.50%). After the first VTP, 69.81% of women used contraceptive methods classified as “very effective” according to the World Health Organization. The risk factors identified as being associated with recurrent VTP included being part of the state-subsidized health insurance system (adjusted odds ratio [aOR] = 1.35; 95 % CI:1.05-1.72) and having had two or more pregnancies (aOR = 1.23; 95% CI: 1.06 - 1.44). Protective factors were identified and included out-of-pocket payment for VTP service (aOR = 0.71; 95% CI: 0.61-0.82), a history of late VTP (aOR = 0.30; 95% CI: 0.11-0.81), and the selection of a subdermal implant for contraception following the first abortion (sOR = 0.64; 95% CI: 0.49 – 0.83).</p><p><strong>Conclusions: </strong>It is possible that the prevalence of recurrent VTP is increasing. Prospective studies are required in order to determine whether there is a growing trend and to verify potential association hypotheses derived from this work.</p>","PeriodicalId":101422,"journal":{"name":"Revista colombiana de obstetricia y ginecologia","volume":"74 4","pages":"276-286"},"PeriodicalIF":0.0,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139992276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}